1421312-32-4

Basic information

• Product Name: C₁₇H₁₃NO₅
• Synonyms: C₁₇H₁₃NO₅
• CAS NO: 1421312-32-4
• Molecular Weight: 311.294
• Mol File: 1421312-32-4.mol

Chemical Properties

• Boiling Point: 556.6±50.0 °C(Predicted)
• Density: 1.394±0.06 g/cm3(Predicted)
• CAS DataBase Reference: C₁₇H₁₃NO₅(CAS DataBase Reference)
• NIST Chemistry Reference: C₁₇H₁₃NO₅(1421312-32-4)
• EPA Substance Registry System: C₁₇H₁₃NO₅(1421312-32-4)

Safety Data

• Hazardous Substances Data: 1421312-32-4(Hazardous Substances Data)

Upstream product

• 1421312-31-3 C₁₈H₁₃NO₆ 
• 21345-01-7 4-phenoxyphthalic anhydride 
• 37951-15-8 4-phenoxyphthalic acid 
• 38791-62-7 4-phenoxyphthalonitrile 
• 31643-49-9 4-Nitrophthalonitrile 

Downstream Products

• 808118-40-3 [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid 
• 1421312-33-5 methyl 4-hydroxy-1-chloro-7-phenoxyisoquinoline-3-carboxylate 
• 1421312-34-6 4-hydroxy-1-methyl-7-phenoxyisoquinolinyl-3-carboxylic acid methyl ester 
• 1421312-35-7 4-hydroxy-1-methyl-7-phenoxy-3-isoquinolinecarboxylic acid 
• 1421312-36-8 [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)amino]acetic acid methyl ester 

Relevant articles and documents

Preparation method of roxadustat intermediate

The invention discloses a preparation method of a roxadustat intermediate. The method comprises the following steps: anhydride ring opening, esterification, ring closing, aromatization, deprotection, chlorination and methylation to obtain the roxadustat intermediate. According to the invention, the preparation method provided by the invention makes full use of the atom economy theory, is easy to operate, low in cost and low in pollution, and is suitable for large-scale industrial production; and only one-time refining is carried out, the chromatographic purity can reach 99.5% or above, and the total yield of the six-step reaction is 30% or above.

Preparation method of drug for chronic anemia

The invention discloses a synthesis method for a drug Roxadustat for chronic anemia. The synthesis method comprises the following steps: hydrolyzing and acidifying a compound shown as a formula 6 under the action of alkali to obtain a key intermediate compound shown as a formula 7; carrying out condensation reaction on the compound shown as the formula 7 and carbonyl diimidazole under suitable conditions to obtain an intermediate compound shown as a formula 8, and separating or not separating the compound shown as the formula 8 from a system to directly take part in subsequent reaction; and finally, reacting the product with glycine to obtain a final product Roxadustat shown as a formula 9. The preparation method has the advantages that the route efficiency is improved, the process cost isreduced, side products are reduced and the purity of a final product is favorably improved (The formula is shown in the description), wherein R2 in the compound shown as the formula 6 represents alkyl, and includes but not limited to methyl, ethyl, isopropyl, tertiary butyl or benzyl.

CRYSTAL TYPES OF COMPOUNDS INHIBITING ACTIVITY OF PROLYL HYDROXYLASE AND USE THEREOF

The invention relates to crystal types of compound shown as structural formula I, methods of preparing the compound, intermediate, pharmaceutical composition, and use of treating disease or pharmaceutical preparations for treating disease.

POLYMORPHIC FORMS OF COMPOUNDS AS PROLYL HYDROXYLASE INHIBITOR, AND USES THEREOF

The present invention relates to the polymorphic forms of the compound of Formula (I), preparation thereof including the preparation of intermediates and pharmaceutical compositions, and use of a polymorph above in the treatment of a disease, a disorder o

POLYMORPHIC FORMS OF COMPOUNDS AS PROLYL HYDROXYLASE INHIBITOR, AND USES THEREOF

The present invention relates to the polymorphic forms of the compound of Formula (I), preparation thereof including the preparation of intermediates and pharmaceutical compositions, and use of a polymorph above in the treatment of a disease, a disorder o